$1.66
+0.03 (+1.84%)
Open$1.64
Previous Close$1.63
Day High$1.71
Day Low$1.62
52W High$3.79
52W Low$0.82
Volume—
Avg Volume435.5K
Market Cap14.67M
P/E Ratio—
EPS$-3.15
SectorBiotechnology
Analyst Ratings
Strong Buy
8 analysts
Price Target
+1,657.8% upside
Current
$1.66
$1.66
Target
$29.18
$29.18
$17.82
$29.18 avg
$40.31
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 9.45M | 8.50M | 8.91M |
| Net Income | 239.2K | 243.9K | 245.4K |
| Profit Margin | 2.5% | 2.9% | 2.8% |
| EBITDA | 403.0K | 435.3K | 434.6K |
| Free Cash Flow | 313.2K | 273.2K | 249.3K |
| Rev Growth | +19.1% | +23.4% | +6.1% |
| Debt/Equity | 0.60 | 0.55 | 0.53 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $265.21 | +0.28% | 74.0 | 466.74B |
| AMGN | Amgen Inc | $410.24 | +4.34% | 23.7 | 207.25B |
| GILD | Gilead Sciences Inc | $152.67 | +1.40% | — | 187.10B |
| VRTX | Vertex Pharmaceuticals Inc | $514.99 | +0.84% | 29.7 | 130.64B |
| REGN | Regeneron Pharmaceuticals | $803.90 | +0.72% | 18.6 | 80.58B |
| ALNY | Alnylam Pharmaceuticals Inc | $251.65 | +3.00% | 40.0 | 32.33B |